Physician profile
Kamal Kamel
NPI 1013296292
$2,165.90
in general payments reported to CMS, 2019-2025
14 companies · $57.72 in 2025
The $57.72 reported for 2025 was less than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2020: $204 · 2021: $510 · 2022: $790 · 2023: $25.03 · 2024: $438 · 2025: $57.72.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $520.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,177.93 | 2019-2024 | Xarelto |
| Amgen INC. | $279.52 | 2022-2024 | Repatha |
| Impulse Dynamics (USA) INC. | $140.63 | 2024 | Optimizer |
| Astrazeneca Pharmaceuticals LP | $99.99 | 2022 | |
| Lilly USA, LLC | $98.27 | 2022 | |
| Daiichi Sankyo INC. | $96.76 | 2022 | |
| Novartis Pharmaceuticals Corporation | $78.63 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $47.05 | 2024 | Zerbaxa, Dificid, Prevymis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $34.16 | 2024 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $30.07 | 2024-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.77 | 2024 | Jardiance |
| Ceribell, INC. | $23.01 | 2025 | Pocket Eeg Device |
| Pfizer INC. | $19.97 | 2025 | |
| Teva Pharmaceuticals USA, INC. | $14.14 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kamal Kamel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.